What are the main functions and efficacy of ruxolitinib tablets/ruxolitinib?

Ruxolitinib Tablets/Ruxolitinib (JAKAVI) is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK2. It is a targeted therapy drug and is mainly used to treat hematological diseases caused by abnormal activation of the JAK-STAT signaling pathway. The JAK-STAT pathway plays an important regulatory role in normal hematopoiesis. However, in some myeloproliferative diseases, such as myelofibrosis (MF), polycythemia vera (PV), and graft-versus-host disease (GVHD), this signaling system is abnormally activated, triggering excessive cell growth and inflammatory responses.

The main mechanism of action of ruxolitinib is to reduce the expression of various pro-inflammatory cytokines (such as IL-6, IL-23, IFN-γ, etc.) by inhibiting the activities ofJAK1 and JAK2, thereby reducing chronic inflammation and improving disease-related symptoms. In the treatment of myelofibrosis, ruxolitinib can effectively reduce splenomegaly, relieve systemic symptoms such as weakness, night sweats, and weight loss related to myelofibrosis, and delay the progression of the disease. In the treatment of polycythemia vera, ruxolitinib can control excessive red blood cell production, reduce blood cell counts, and reduce the occurrence of complications such as venous thrombosis. It also provides a new treatment option for patients who are ineffective or intolerant to hydroxyurea. In addition, in the treatment of graft-versus-host disease (GVHD), especially in patients with acute or chronic GVHD who are unresponsive to glucocorticoids, ruxolitinib is considered one of the first-line backup treatment options, and its anti-inflammatory and immunomodulatory effects significantly improve the prognosis of patients.

In general, ruxolitinib, as aJAK inhibitor, not only shows clear efficacy in disease relief, but also has positive significance in improving patients' quality of life and prolonging progression-free survival. The drug has been recommended by multiple international guidelines for the treatment of myeloproliferative tumors and GVHD. With the expansion of indications and in-depth clinical research, its therapeutic potential is still expanding.

Reference materials:https://www.jakavi.com/